<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:55:56Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5089920" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5089920</identifier>
        <datestamp>2017-05-23</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">101083949</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">22416</journal-id>
              <journal-id journal-id-type="nlm-ta">Pharmacogenomics J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Pharmacogenomics J.</journal-id>
              <journal-title-group>
                <journal-title>The pharmacogenomics journal</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1470-269X</issn>
              <issn pub-type="epub">1473-1150</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5089920</article-id>
              <article-id pub-id-type="pmcid">PMC5089920</article-id>
              <article-id pub-id-type="pmc-uid">5089920</article-id>
              <article-id pub-id-type="pmid">27019981</article-id>
              <article-id pub-id-type="pmid">27019981</article-id>
              <article-id pub-id-type="doi">10.1038/tpj.2016.7</article-id>
              <article-id pub-id-type="manuscript">nihpa755122</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alachkar</surname>
                    <given-names>Houda</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fulton</surname>
                    <given-names>Noreen</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sanford</surname>
                    <given-names>Ben</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Malnassy</surname>
                    <given-names>Greg</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mutonga</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Larson</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bloomfield</surname>
                    <given-names>Clara D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marcucci</surname>
                    <given-names>Guido</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nakamura</surname>
                    <given-names>Yusuke</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stock</surname>
                    <given-names>Wendy</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Department of Pharmacy, USC School of Pharmacy, University of Southern California, Los Angeles, CA</aff>
              <aff id="A2"><label>2</label>Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL</aff>
              <aff id="A3"><label>3</label>Alliance/CALGB Statistical Center, Duke Cancer Institute, Biostatistics, Durham, NC</aff>
              <aff id="A4"><label>4</label>Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH</aff>
              <aff id="A5"><label>5</label>Gehr Family Center for Leukemia, City of Hope Comprehensive Cancer Center, Duarte, CA</aff>
              <author-notes>
                <corresp id="CR1"><bold>Address reprint requests to:</bold> Wendy Stock MD, Professor of Medicine, Section of Hematology/Oncology, The University of Chicago, 900 E 57<sup>th</sup> St, Chicago, IL 60637, <email>wstock@medicine.bsd.uchicago.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>5</day>
                <month>2</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>3</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>5</month>
                <year>2017</year>
              </pub-date>
              <volume>17</volume>
              <issue>3</issue>
              <fpage>274</fpage>
              <lpage>279</lpage>
              <!--elocation-id from pubmed: 10.1038/tpj.2016.7-->
              <permissions>
                <license>
                  <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
                </license>
              </permissions>
              <abstract>
                <p id="P1">Asparaginase, which depletes asparagine and glutamine, activates amino acid stress response. Oxidative stress mediated by excessive reactive oxygen species (ROS) causes enhanced mitochondrial permeabilization and subsequent cell apoptosis and is considered a plausible mechanism for drug-induced hepatotoxicity, a common toxicity of asparaginase in adults with acute lymphoblastic leukemia (ALL). Studies investigating the pharmacogenetics of asparaginase in ALL are limited and focused on asparaginase-induced allergic reaction common in pediatric patients. Here, we sought to determine a potential association between the variant rs4880 in <italic>SOD2</italic> gene, a key mitochondrial enzyme that protects cells against ROS, and hepatotoxicity during asparaginase-based therapy in 224 patients enrolled on CALGB-10102, a treatment trial for adults with ALL. We report that the CC genotype of rs4880 is associated with increased hepatotoxicity following asparaginase-based treatment. Thus, rs4880 likely contributes to asparaginase-induced hepatotoxicity, and functional studies investigating this SNP are needed to develop therapeutic approaches that mitigate this toxicity.</p>
              </abstract>
              <kwd-group>
                <kwd>Acute Lymphoblastic Leukemia</kwd>
                <kwd>Asparaginase</kwd>
                <kwd>SOD2</kwd>
                <kwd>rs4880</kwd>
                <kwd>polymorphism</kwd>
                <kwd>hepatotoxicity</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="S1">
              <title>Introduction</title>
              <p id="P2">The intensive use of asparaginase is an essential component of pediatric regimens for acute lymphoblastic leukemia (ALL) and has been associated with significant improvements in survival. Accordingly, many attempts have incorporated asparaginase in treatment regimens for adults with ALL; yet, the higher rate of asparaginase-related toxicities in adults with ALL have limited its widespread use and new insights are needed. (<xref rid="R1" ref-type="bibr">1</xref>) Studies investigating the pharmacogenetics of asparaginase in ALL are limited and mostly focused on pediatric patients with ALL. A recent study investigated more than 500,000 single nucleotide polymorphisms (SNPs) in 485 children with ALL and found an association of five SNPs in the <italic>GRIA1</italic> gene with hypersensitivity to the drug.(<xref rid="R2" ref-type="bibr">2</xref>) The same group also tested more than 2 million SNPs using the HapMap lymphoblastoid cell lines and identified the aspartate metabolic routes as the most likely candidate pathway for asparaginase sensitivity.(<xref rid="R3" ref-type="bibr">3</xref>) In addition, polymorphisms in genes that mediate the antileukemic effect of asparaginase, such as the asparaginase synthetase gene, the basic region leucine zipper activating transcription factor 5, and the argininosuccinate synthase 1 gene, were found to be associated with reduced event-free survival of childhood patients with ALL, but not with toxicity.(<xref rid="R4" ref-type="bibr">4</xref>)</p>
              <p id="P3">While asparaginase allergy is the main toxicity observed in children, hepatotoxicity is one of the most common toxicities of this drug in adults with ALL and often limits the use of this effective drug in this age group.(<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R5" ref-type="bibr">5</xref>) The incidence rate of elevated liver enzymes and hyperbilirubinemia (grade 3 or 4) was reported to be 36% and 14%, respectively, in adults compared to 20% and 3% in pediatric patients.(<xref rid="R1" ref-type="bibr">1</xref>) Studies that focused on exploring these toxicities in association with polymorphisms in adult ALL are still limited.</p>
              <p id="P4">Superoxide dismutase (SOD), an enzyme that catalyzes the dismutation of superoxide (O2<sup>−</sup>) into oxygen and hydrogen peroxide, is a crucial antioxidant that protects cells against oxidative stress. Three forms of SOD enzymes are present in mammalian cells; cytoplasmic superoxide dismutase (SOD1), mitochondrial superoxide dismutase (SOD2), and extracellular superoxide dismutase (SOD3).(<xref rid="R6" ref-type="bibr">6</xref>) Two previous studies have reported that the SOD2 polymorphism causing a V16A amino-acid substitution (rs4880) is significantly associated with drug induced liver injury (DILI).(<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>) Recently, the same polymorphism was found to be significantly correlated with breast cancer survival after cyclophosphamide-containing chemotherapy.(<xref rid="R9" ref-type="bibr">9</xref>)</p>
              <p id="P5">Here we studied 224 patients enrolled on CALGB 10102, a treatment trial for adults with previously untreated ALL who received L-asparaginase as part of their chemotherapy regimen. The aim of the study is to investigate potential associations between the <italic>SOD2</italic> rs4880 polymorphism and asparaginase-related hepatotoxicity in adult patients with ALL. Secondary objectives of this study are to assess a possible correlation between this polymorphism and ALL susceptibility in adults, and to determine whether this polymorphism is associated with <italic>SOD2</italic> transcript levels as a possible mechanism for this functional variant. Here we also genotyped rs4958351 in the <italic>GRIA1</italic> gene, one of the SNPs that was previously identified to be associated with hypersensitivity to asparaginase in children with ALL. (<xref rid="R2" ref-type="bibr">2</xref>)</p>
            </sec>
            <sec sec-type="methods" id="S2">
              <title>Materials and Methods</title>
              <sec id="S3">
                <title>Patient population</title>
                <p id="P6">We studied samples obtained from 224 patients with previously untreated ALL, enrolled on a national clinical trial for adults with ALL {Cancer and Leukemia Group B [CALGB] trial 10102}. Informed consent to use the tissue for investigational studies was obtained from each patient enrolled on the trial and according to institutional guidelines. Complete clinical data was available for 221 of 224 patients. Samples at remission (after Cycle III of treatment) were available from 196 patients for DNA extraction and genotyping. Paired samples of pretreatment and post remission peripheral blood (bone marrow paired samples were obtained from two patients) samples from 30 patients were available for RNA analysis. Remission samples (after Cycle III of treatment) obtained from 86 patients were used for RNA analysis and correlation with hepatotoxicity and genotypes (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p>
                <p id="P7">By Cycle III of the treatment regimen on the CALGB 10102 protocol, patients would have received the following chemotherapy: Cyclophosphamide, Daunorubicin, Vincristine, L-asparaginase, Cytarabine, Methotrexate, and 6-Mercaptopurine. L-asparaginase was given as 6000 U/m<sup>2</sup> SC or IM twice a week for six doses beginning on day 5 during the first month of treatment and on days 15, 18 and 22 during the 2<sup>nd</sup> and 4<sup>th</sup> month of treatment. Common Terminology Criteria for Adverse Events v4.0 (<italic>CTCAE</italic>) was used to grade hepatotoxicity.</p>
              </sec>
              <sec id="S4">
                <title>RNA extraction and Real-time quantitative PCR</title>
                <p id="P8">Total RNA was isolated from bone marrow and peripheral blood samples using Trizol reagent (Life Technologies Carlsbad, CA, USA). cDNA was synthesized using SuperScript III reagents (Life technologies) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using commercially available TaqMan Gene Expression Assay primers and probes for <italic>SOD2</italic> and <italic>B2M</italic> and the LightCycler 480II Real-Time PCR System (Roche, Basel, Switzerland). The expression levels were normalized to <italic>B2M</italic> gene expression.</p>
              </sec>
              <sec id="S5">
                <title>DNA extraction and genotyping</title>
                <p id="P9">Genotyping was performed using the TaqMan Allelic Discrimination Assay for rs4880 of <italic>SOD2</italic> gene and rs4958351 in the <italic>GRIA1</italic> gene (Life Technologies). The PCR was carried out using The LightCycler<sup>®</sup> 480II System (Roche). After PCR, fluorescence from reaction products was measured and analyzed using the System LightCycler<sup>®</sup> 480 Software.</p>
              </sec>
              <sec id="S6">
                <title>Statistical analysis</title>
                <p id="P10">We tested agreement with the Hardy-Weinberg Equilibrium using a χ<sup>2</sup> goodness-of-fit test for rs4880. Because 84% of patients with ALL in our study reported to be white, we used genotyping data obtained in European cohorts, after excluding patients of Hispanics origin (N=16). We then compared genotype frequencies of the polymorphisms between cases with ALL and reported frequencies obtained from the NCBI European cohort data sets (ESP-cohort, Hap-Map-CEU and CEU-GENO). We also compared genotype frequencies in Hispanic patients with ALL and Hispanic/Latino/Mexican-American cohort data set (HSP-geno-panel). We used the Fisher Exact two-tail test, and calculated odds ratios (ORs) with 95 percent confidence intervals (95% CI). In the association study, P values of less than 0.05 were considered to be statistically significant. Expression levels of <italic>SOD2</italic> transcripts between three or two groups were tested with the Kruskal-Wallis test or an unpaired Mann-Whitney test, respectively. The Chi-square test was then used to compare differences in allele frequencies and genotype distribution of the polymorphism between patients with hepatotoxicity and those without. The Fisher Exact test was used to test the recessive model.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="S7">
              <title>Results</title>
              <sec id="S8">
                <title>Patient population and hepatotoxicity data</title>
                <p id="P11">We studied samples obtained from 224 patients with ALL. Demographic and clinical data were available for 221 patients (age range, 17–80 years; median age, 43.9 years; 85 female and 136 male), enrolled on treatment trial (CALGB protocol 10102) for adults with ALL. Asparaginase hepatotoxicity was estimated by assessing the following clinical laboratory markers: aspartate transaminase (AST), alanine transaminase (ALT), albumin, alkaline phosphatase, and bilirubin levels in patients following induction and two cycles of post-remission therapy. Among the 221 patients, 51 (23%) patients had grade 3 or 4 elevated AST levels, and 82 (37%) patients had grade 3 or 4 elevated ALT levels, 53 (24%) patients had grade 3 or 4 elevated bilirubin levels. AST and ALT levels may be increased several folds above normal in hepatocyte injury. On the other hand, elevations of alkaline phosphatase and bilirubin levels predominate in cholestatic syndromes (<xref rid="R10" ref-type="bibr">10</xref>). Therefore, we defined hepatotoxicity as grade 3/4 of both AST and ALT, grade 4 of either AST or ALT, or grade 3/4 of bilirubin elevation. Using this classification, we identified 73 patients (33.03%) meeting these criteria (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
              </sec>
              <sec id="S9">
                <title>Genotyping analysis for <italic>SOD2</italic> rs4880 in patients with ALL</title>
                <p id="P12">DNA samples from 196 patients with ALL were genotyped for <italic>SOD2</italic> rs4880 and GRIA1 rs4958351. Among these, four samples were excluded from the <italic>SOD2</italic> rs4880 analysis due to poor discrimination/quality of genotyping results. The genotypes of the remaining 192 samples were used for further analysis. Our genotyping results showed a minor allelic frequency of 0.52 (for the C allele). Among the 192 patients, 48 patients had a TT genotype (25%), 55 patients had a CC genotype (28.6%), and 89 patients had a CT genotype (46%). These results did not deviate from the Hardy-Weinberg equilibrium (Chi-square (χ<sup>2</sup>) test P=0.32 with 1 degree of freedom).</p>
                <p id="P13">We compared genotype frequencies of <italic>SOD2</italic> rs4880 obtained from our data set of patients with ALL, with publicly available databases. Because 84% of the patients enrolled on CALGB 10102 were Caucasian, we compared our results of <italic>SOD2</italic> rs4880 genotype frequencies obtained from 192 patients with data from public data bases of European cohorts. We found that the frequency of the CC genotype (28.6%) in our data set was significantly higher than that (14.8%) of the CEUGENO; (two tailed Fisher's Exact test; P=0.007, <xref ref-type="table" rid="T2">Table 2</xref>). Higher frequency of the CC genotype was also found in the population of patients with ALL when compared with that in the ESP cohort (P=0.029) or the Hap-Map-CEU cohort (P=0.14; <xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="supplementary-material" rid="SD2">S2</xref>). Since the rs4880 CC genotype is more frequent in the Hispanic population, we reanalyzed the samples after excluding patients of Hispanic ethnicity (N=16). We found that the frequency of the CC genotype remained higher in patients with ALL in comparison with the CEU-GENO panel (P=0.049) and a trend for higher frequency was observed when we compared our data with that of the ESP or Hap-Map-CEU cohorts. In patients with ALL of Hispanic ethnicity, we found the rs4880 genotype CC present in 8 out of 16 (50%) patients, while the TT genotype was only present in 1 patient (6%). The frequencies of CC, CT and TT in the reported database of Hispanic ethnicity (HSP-GENO-panel cohort; N=108) are 33%, 38% and 27% respectively. Although the numbers are small, nevertheless a trend for higher frequency of the CC genotype was present in patients with ALL of Hispanics origin in comparison with that in the HSP-GENO cohort (P=0.165).</p>
                <p id="P14">On the other hand, among the 196 patients genotyped for <italic>GRIA1</italic> rs4958351 there were: 21 or 10.7% AA; 86 or 43.8% AG; and 89 or 45.4% GG. The MAF was 0.33, and the genotyping results did not deviate from the Hardy-Weinberg equilibrium (Chi-square (χ<sup>2</sup>) test P = 0.97 with 1 degree of freedom). The observed frequency distribution was similar to that of the Hap-Map-CEU population (P=0.98, <xref ref-type="supplementary-material" rid="SD3">Table S3</xref>).</p>
              </sec>
              <sec id="S10">
                <title>Association of <italic>SOD2</italic> polymorphism rs4880 and hepatotoxicity</title>
                <p id="P15">We analyzed 221 patients for whom hepatotoxicity data were available; among them we obtained genotyping data on 190 patients for <italic>SOD2</italic> rs4880, and 193 patients for <italic>GRIA1</italic> rs4958351. Two and three patients with genotyping data but no hepatotoxicity data were excluded from the analysis of rs4880 and rs4958351, respectively. The correlation between the rs4880 genotype and hepatotoxicity parameters is shown in <xref ref-type="table" rid="T3">Table 3</xref>. Grade 3 and 4 of bilirubinemia was found more frequently in patients with the <italic>SOD2</italic> rs4880 CC genotype compared with those with the CT genotype (Fisher Exact test P=0.055). In addition, the <italic>SOD2</italic> rs4880 CC genotype was associated with a trend towards more serious (Grade 4) hepatotoxicity compared with the rs4880 CT or TT genotypes (P=0.09). Albumin levels did not correlate significantly with rs4880 genotype.</p>
                <p id="P16">As previously described, we defined hepatotoxicity as grade 3/4 of both AST and ALT, grade 4 of either AST or ALT, or grade 3/4 bilirubin elevation. Using this classification, we identified 61 of the 190 patients (32%) meeting these criteria. We tested the possible genetic models (dominant, recessive, or additive effect). We found that only the CC genotype was associated with increased risk of hepatotoxicity (Chi-square test P=0.018, OR=2.6, 95% CI 1.1-6.07; P=0.026 when CC vs TT were compared, OR=2.5 95% CI 1.2-5.1; P=0.01 when CC vs CT were compared) suggesting a recessive model. Therefore we implemented the recessive model for further analysis and found that patients with the <italic>SOD2</italic> rs4880 CC genotype had a significantly higher frequency of hepatotoxicity than those with the TT or CT genotypes (Fisher Exact test P=0.006; OR=2.53; 95% CI 1.3-4.8; <xref ref-type="table" rid="T3">Table 3</xref> and <xref ref-type="fig" rid="F1">Figure 1, A and B</xref>). <italic>GRIA1</italic> rs4958351 did not show a significant association with hepatotoxicity except and association with elevated ALK-Phos, (<xref ref-type="supplementary-material" rid="SD4">Table S4</xref>).</p>
              </sec>
              <sec id="S11">
                <title><italic>SOD2</italic> mRNA expression in patients with ALL</title>
                <p id="P17">Next we sought to examine <italic>SOD2</italic> mRNA levels in cells obtained from patients with ALL, assess changes in <italic>SOD2</italic> mRNA levels following treatment, and correlate these levels with hepatotoxicity. <italic>SOD2</italic> mRNA expression was measured by RT-PCR in samples obtained from patients with ALL (N=86) that completed induction therapy and two post remission cycles on CALGB10102. <italic>SOD2</italic> mRNA levels were not significantly different between patients with hepatotoxicity, and those without (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Patients were dichotomized into <italic>SOD2</italic> high expressers and <italic>SOD2</italic> low expressers, using the median expression as the cut off. No significant correlation was observed when we assessed each toxicity parameter, or toxicity with grade 3 and higher.</p>
                <p id="P18">In those patients, for whom we had paired samples (pretreatment and post remission, N=30) for, we analyzed changes in <italic>SOD2</italic> mRNA expression changes. Interestingly, <italic>SOD2</italic> mRNA expression was significantly lower in pretreatment samples in comparison to remission samples (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Although rs4880 is known to affect the mitochondrial translocation of SOD2, in order, to exclude other possible transcriptional regulatory mechanisms for this SNP, we examined the expression of <italic>SOD2</italic> mRNA in pretreatment (N=25) and remission (N=86) samples relative to the rs4880 genotype. We did not observe significant correlation between <italic>SOD2</italic> mRNA levels prior to, or during treatment and rs4880 genotypes (<xref ref-type="fig" rid="F3">Figure 3A,B</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="S12">
              <title>Discussion</title>
              <p id="P19">Asparaginase, which depletes asparagine and glutamine, activates an amino acid stress response. Similar to other cytotoxic agents, the anti-cancer activity is associated with oxidative stress, which is mediated by excessive reactive oxygen species (ROS), resulting in elevated mitochondrial permeabilization and subsequent cell apoptosis.(<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>) This process is thought to represent a common mechanism of drug-induced hepatotoxicity. High ROS levels resulting from variability in the function or expression of enzymes involved in these pathways may affect therapeutic outcomes and toxicities.(<xref rid="R13" ref-type="bibr">13</xref>)</p>
              <p id="P20">SOD2 is located predominantly in the mitochondrial matrix and plays an important role in the detoxification of mitochondrial superoxide (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>) by converting superoxide into hydrogen peroxide and oxygen.(<xref rid="R16" ref-type="bibr">16</xref>) This enzyme is indispensable for cell survival; while, homozygous SOD2-deficient mice die shortly after birth, (<xref rid="R17" ref-type="bibr">17</xref>) heterozygous SOD2-deficient mice are viable but present with increased susceptibility to chemical-induced mitochondrial toxicity in the liver. (<xref rid="R18" ref-type="bibr">18</xref>-<xref rid="R20" ref-type="bibr">20</xref>) This suggests an important role of this gene in protecting the liver from drug-induced toxicities.</p>
              <p id="P21">The polymorphism rs4880 in <italic>SOD2</italic> results in the incorporation of either alanine (C allele) or valine (T allele) in the mitochondrial targeting sequence of the protein. The alanine form of SOD2 is transported normally into the mitochondria, while the protein with valine is partially trapped in the inner mitochondrial membrane.(<xref rid="R21" ref-type="bibr">21</xref>) Although this suggests that the T allele would be associated with lower enzymatic efficiency, higher levels of ROS and greater risk of cancer and toxicities, most pharmacogenomic correlative studies have implicated the C allele as a risk allele for cancer.(<xref rid="R22" ref-type="bibr">22</xref>-<xref rid="R24" ref-type="bibr">24</xref>) Here we reveal that the CC genotype, but not CT or TT, is likely present at higher frequencies in patients with ALL. We also found this genotype to be more frequent in the Hispanic cohort and are known to have a higher incidence of ALL compared to other ethnicities.(<xref rid="R25" ref-type="bibr">25</xref>) Polymorphisms in <italic>SOD2</italic> have not previously been associated with susceptibility to ALL; perhaps the lack of large pharmacogenomics studies in adult patients with ALL may have previously limited the statistical power to identify this locus.</p>
              <p id="P22">Importantly, in this study we found that the CC genotype was associated with asparaginase related hepatotoxicity in adult patients with ALL. Patients in the study have also received methotrexate and 6-Mercaptopurine, both drugs may contribute to the elevation in transaminases and hepatotoxicity. Liver enzymes and bilirubin levels are measured regularly to monitor asparaginase-associated hepatotoxicity. Current clinical guidelines recommend holding asparaginase treatment in adult when grade 3–4 hepatotoxicity develops and then re-challenging with careful monitoring if toxicity resolves to grade 1, often resulting in prolonged delays in treatment and suboptimal dosing which may impair treatment outcomes. (<xref rid="R1" ref-type="bibr">1</xref>) Therefore the findings resulted from our pharmacogenomic approach may have important clinical implications.</p>
              <p id="P23">Interestingly, <italic>SOD2</italic> transcript levels were significantly higher in samples obtained at remission compared to those obtained at diagnosis. This may be attributed to the different cell composition, being leukemic cells in the diagnosis samples and normal cells in the remission samples. Asparaginase induced <italic>SOD2</italic> mRNA upregulation, may also contribute to this finding. The transcript levels of <italic>SOD2</italic> did not correlate with this polymorphism, or differ between patients with and without hepatotoxicity. Previous studies have shown that this variant affected the enzymatic activity but not the transcript level of SOD2. SOD2 activity has been reported to be 33% higher in CT or TT individuals compared to CC individuals.(<xref rid="R26" ref-type="bibr">26</xref>) While we recognize that our study is limited by the relatively small number of patients analyzed and the lack of a control cohort, our data suggest that genetic variation in the <italic>SOD2</italic> gene is associated with susceptibility to ALL in this adult cohort and is associated with treatment related hepatic toxicities; thus, a larger cohort is required to validate these findings. Furthermore, functional studies that investigate this genetic association are needed in order to develop therapeutic approaches that might mitigate this toxicity.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>1</label>
                <media xlink:href="NIHMS755122-supplement-1.tif" orientation="portrait" xlink:type="simple" id="d36e562" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD2">
                <label>2</label>
                <media xlink:href="NIHMS755122-supplement-2.tif" orientation="portrait" xlink:type="simple" id="d36e566" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD3">
                <label>3</label>
                <media xlink:href="NIHMS755122-supplement-3.tif" orientation="portrait" xlink:type="simple" id="d36e570" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD4">
                <label>4</label>
                <media xlink:href="NIHMS755122-supplement-4.tif" orientation="portrait" xlink:type="simple" id="d36e574" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S13">
              <title>Acknowledgements</title>
              <p>We would like to thank the University of Chicago Cancer Research Foundation Women's Board and Division of Biological Sciences. This work was also supported by the following grants: NIH grants: T32GM007019, UM1 CA186705 and P30 CA14599-36.</p>
            </ack>
            <fn-group>
              <fn id="FN1">
                <p id="P24">Conflict of interest</p>
                <p id="P25">Authors do not have any conflict of interest to declare.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stock</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Douer</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>DeAngelo</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Arellano</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Advani</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Damon</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.</article-title>
                  <source>Leukemia &amp; lymphoma</source>
                  <month>12</month>
                  <year>2011</year>
                  <volume>52</volume>
                  <issue>12</issue>
                  <fpage>2237</fpage>
                  <lpage>53</lpage>
                  <comment>PubMed PMID: 21827361</comment>
                  <pub-id pub-id-type="pmid">21827361</pub-id>
                </element-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Pei</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Jeha</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.</article-title>
                  <source>Clinical pharmacology and therapeutics</source>
                  <month>8</month>
                  <year>2010</year>
                  <volume>88</volume>
                  <issue>2</issue>
                  <fpage>191</fpage>
                  <lpage>6</lpage>
                  <comment>PubMed PMID: 20592726. Pubmed Central PMCID: 3000799</comment>
                  <pub-id pub-id-type="pmid">20592726</pub-id>
                </element-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Fan</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Stocco</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Crews</surname>
                      <given-names>KR</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.</article-title>
                  <source>Leukemia</source>
                  <month>1</month>
                  <year>2011</year>
                  <volume>25</volume>
                  <issue>1</issue>
                  <fpage>66</fpage>
                  <lpage>74</lpage>
                  <comment>PubMed PMID: 21072045. Pubmed Central PMCID: 3097057</comment>
                  <pub-id pub-id-type="pmid">21072045</pub-id>
                </element-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rousseau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gagne</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Labuda</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Beaubois</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Sinnett</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Laverdiere</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.</article-title>
                  <source>Blood</source>
                  <day>24</day>
                  <month>11</month>
                  <year>2011</year>
                  <volume>118</volume>
                  <issue>22</issue>
                  <fpage>5883</fpage>
                  <lpage>90</lpage>
                  <comment>PubMed PMID: 21972289. Pubmed Central PMCID: 3342855</comment>
                  <pub-id pub-id-type="pmid">21972289</pub-id>
                </element-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kearney</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Dahlberg</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Levy</surname>
                      <given-names>DE</given-names>
                    </name>
                    <name>
                      <surname>Voss</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Sallan</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Silverman</surname>
                      <given-names>LB</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.</article-title>
                  <source>Pediatric blood &amp; cancer</source>
                  <month>8</month>
                  <year>2009</year>
                  <volume>53</volume>
                  <issue>2</issue>
                  <fpage>162</fpage>
                  <lpage>7</lpage>
                  <comment>PubMed PMID: 19405141. Pubmed Central PMCID: 2721691</comment>
                  <pub-id pub-id-type="pmid">19405141</pub-id>
                </element-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miao</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>St Clair</surname>
                      <given-names>DK</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulation of superoxide dismutase genes: implications in disease.</article-title>
                  <source>Free radical biology &amp; medicine</source>
                  <day>15</day>
                  <month>8</month>
                  <year>2009</year>
                  <volume>47</volume>
                  <issue>4</issue>
                  <fpage>344</fpage>
                  <lpage>56</lpage>
                  <comment>PubMed PMID: 19477268. Pubmed Central PMCID: 2731574</comment>
                  <pub-id pub-id-type="pmid">19477268</pub-id>
                </element-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>YS</given-names>
                    </name>
                    <name>
                      <surname>Su</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>YH</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>CY</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>FY</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>HC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.</article-title>
                  <source>Journal of hepatology</source>
                  <month>7</month>
                  <year>2007</year>
                  <volume>47</volume>
                  <issue>1</issue>
                  <fpage>128</fpage>
                  <lpage>34</lpage>
                  <comment>PubMed PMID: 17400324</comment>
                  <pub-id pub-id-type="pmid">17400324</pub-id>
                </element-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lucena</surname>
                      <given-names>MI</given-names>
                    </name>
                    <name>
                      <surname>Garcia-Martin</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Andrade</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Martinez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Stephens</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ruiz</surname>
                      <given-names>JD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury.</article-title>
                  <source>Hepatology</source>
                  <month>7</month>
                  <year>2010</year>
                  <volume>52</volume>
                  <issue>1</issue>
                  <fpage>303</fpage>
                  <lpage>12</lpage>
                  <comment>PubMed PMID: 20578157</comment>
                  <pub-id pub-id-type="pmid">20578157</pub-id>
                </element-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Glynn</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Boersma</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Howe</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Edvardsen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Geisler</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Goodman</surname>
                      <given-names>JE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.</article-title>
                  <source>Clinical cancer research : an official journal of the American Association for Cancer Research</source>
                  <day>15</day>
                  <month>6</month>
                  <year>2009</year>
                  <volume>15</volume>
                  <issue>12</issue>
                  <fpage>4165</fpage>
                  <lpage>73</lpage>
                  <comment>PubMed PMID: 19509150. Pubmed Central PMCID: 2697269</comment>
                  <pub-id pub-id-type="pmid">19509150</pub-id>
                </element-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>WM</given-names>
                    </name>
                  </person-group>
                  <article-title>Drug-induced hepatotoxicity.</article-title>
                  <source>The New England journal of medicine</source>
                  <day>31</day>
                  <month>7</month>
                  <year>2003</year>
                  <volume>349</volume>
                  <issue>5</issue>
                  <fpage>474</fpage>
                  <lpage>85</lpage>
                  <comment>PubMed PMID: 12890847</comment>
                  <pub-id pub-id-type="pmid">12890847</pub-id>
                </element-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wilson</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Bunpo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Cundiff</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Wek</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Anthony</surname>
                      <given-names>TG</given-names>
                    </name>
                  </person-group>
                  <article-title>The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.</article-title>
                  <source>American journal of physiology Endocrinology and metabolism</source>
                  <day>1</day>
                  <month>11</month>
                  <year>2013</year>
                  <volume>305</volume>
                  <issue>9</issue>
                  <fpage>E1124</fpage>
                  <lpage>33</lpage>
                  <comment>PubMed PMID: 24002574. Pubmed Central PMCID: 3840205</comment>
                  <pub-id pub-id-type="pmid">24002574</pub-id>
                </element-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costantini</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Jacotot</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Decaudin</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Kroemer</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Mitochondrion as a novel target of anticancer chemotherapy.</article-title>
                  <source>Journal of the National Cancer Institute</source>
                  <day>5</day>
                  <month>7</month>
                  <year>2000</year>
                  <volume>92</volume>
                  <issue>13</issue>
                  <fpage>1042</fpage>
                  <lpage>53</lpage>
                  <comment>PubMed PMID: 10880547</comment>
                  <pub-id pub-id-type="pmid">10880547</pub-id>
                </element-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choi</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Nowell</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Blanco</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Ambrosone</surname>
                      <given-names>CB</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of genetic variability in drug metabolism pathways in breast cancer prognosis.</article-title>
                  <source>Pharmacogenomics</source>
                  <month>6</month>
                  <year>2006</year>
                  <volume>7</volume>
                  <issue>4</issue>
                  <fpage>613</fpage>
                  <lpage>24</lpage>
                  <comment>PubMed PMID: 16753008</comment>
                  <pub-id pub-id-type="pmid">16753008</pub-id>
                </element-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Macmillan-Crow</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Cruthirds</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Invited review: manganese superoxide dismutase in disease.</article-title>
                  <source>Free radical research</source>
                  <month>4</month>
                  <year>2001</year>
                  <volume>34</volume>
                  <issue>4</issue>
                  <fpage>325</fpage>
                  <lpage>36</lpage>
                  <comment>PubMed PMID: 11328670</comment>
                  <pub-id pub-id-type="pmid">11328670</pub-id>
                </element-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zelko</surname>
                      <given-names>IN</given-names>
                    </name>
                    <name>
                      <surname>Mariani</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Folz</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression.</article-title>
                  <source>Free radical biology &amp; medicine</source>
                  <day>1</day>
                  <month>8</month>
                  <year>2002</year>
                  <volume>33</volume>
                  <issue>3</issue>
                  <fpage>337</fpage>
                  <lpage>49</lpage>
                  <comment>PubMed PMID: 12126755</comment>
                  <pub-id pub-id-type="pmid">12126755</pub-id>
                </element-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fridovich</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Superoxide radical and superoxide dismutases.</article-title>
                  <source>Annual review of biochemistry</source>
                  <year>1995</year>
                  <volume>64</volume>
                  <fpage>97</fpage>
                  <lpage>112</lpage>
                  <comment>PubMed PMID: 7574505</comment>
                </element-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lebovitz</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Vogel</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Cartwright</surname>
                      <given-names>J</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                    <name>
                      <surname>Dionne</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice.</article-title>
                  <source>Proceedings of the National Academy of Sciences of the United States of America</source>
                  <day>3</day>
                  <month>9</month>
                  <year>1996</year>
                  <volume>93</volume>
                  <issue>18</issue>
                  <fpage>9782</fpage>
                  <lpage>7</lpage>
                  <comment>PubMed PMID: 8790408. Pubmed Central PMCID: 38506</comment>
                  <pub-id pub-id-type="pmid">8790408</pub-id>
                </element-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Williams</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Van Remmen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Conrad</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>Epstein</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice.</article-title>
                  <source>The Journal of biological chemistry</source>
                  <day>23</day>
                  <month>10</month>
                  <year>1998</year>
                  <volume>273</volume>
                  <issue>43</issue>
                  <fpage>28510</fpage>
                  <lpage>5</lpage>
                  <comment>PubMed PMID: 9774481</comment>
                  <pub-id pub-id-type="pmid">9774481</pub-id>
                </element-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ong</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Leow</surname>
                      <given-names>KY</given-names>
                    </name>
                    <name>
                      <surname>Khoo</surname>
                      <given-names>YM</given-names>
                    </name>
                    <name>
                      <surname>Boelsterli</surname>
                      <given-names>UA</given-names>
                    </name>
                  </person-group>
                  <article-title>Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2(+/−) mice.</article-title>
                  <source>Free radical biology &amp; medicine</source>
                  <day>1</day>
                  <month>2</month>
                  <year>2006</year>
                  <volume>40</volume>
                  <issue>3</issue>
                  <fpage>420</fpage>
                  <lpage>9</lpage>
                  <comment>PubMed PMID: 16443156</comment>
                  <pub-id pub-id-type="pmid">16443156</pub-id>
                </element-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Larosche</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Letteron</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Berson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fromenty</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>Moreau</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hepatic mitochondrial DNA depletion after an alcohol binge in mice: probable role of peroxynitrite and modulation by manganese superoxide dismutase.</article-title>
                  <source>The Journal of pharmacology and experimental therapeutics</source>
                  <month>3</month>
                  <year>2010</year>
                  <volume>332</volume>
                  <issue>3</issue>
                  <fpage>886</fpage>
                  <lpage>97</lpage>
                  <comment>PubMed PMID: 20016022</comment>
                  <pub-id pub-id-type="pmid">20016022</pub-id>
                </element-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sutton</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Khoury</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Prip-Buus</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cepanec</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pessayre</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Degoul</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria.</article-title>
                  <source>Pharmacogenetics</source>
                  <month>3</month>
                  <year>2003</year>
                  <volume>13</volume>
                  <issue>3</issue>
                  <fpage>145</fpage>
                  <lpage>57</lpage>
                  <comment>PubMed PMID: 12618592</comment>
                  <pub-id pub-id-type="pmid">12618592</pub-id>
                </element-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ambrosone</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>Freudenheim</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Bowman</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Vena</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Marshall</surname>
                      <given-names>JR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer.</article-title>
                  <source>Cancer research</source>
                  <day>1</day>
                  <month>2</month>
                  <year>1999</year>
                  <volume>59</volume>
                  <issue>3</issue>
                  <fpage>602</fpage>
                  <lpage>6</lpage>
                  <comment>PubMed PMID: 9973207</comment>
                  <pub-id pub-id-type="pmid">9973207</pub-id>
                </element-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Woodson</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tangrea</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Lehman</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Modali</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Snyder</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland).</article-title>
                  <source>Cancer causes &amp; control : CCC</source>
                  <month>8</month>
                  <year>2003</year>
                  <volume>14</volume>
                  <issue>6</issue>
                  <fpage>513</fpage>
                  <lpage>8</lpage>
                  <comment>PubMed PMID: 12948282</comment>
                  <pub-id pub-id-type="pmid">12948282</pub-id>
                </element-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hung</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Boffetta</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Brennan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Malaveille</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gelatti</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Placidi</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk.</article-title>
                  <source>Carcinogenesis</source>
                  <month>6</month>
                  <year>2004</year>
                  <volume>25</volume>
                  <issue>6</issue>
                  <fpage>973</fpage>
                  <lpage>8</lpage>
                  <comment>PubMed PMID: 14729580</comment>
                  <pub-id pub-id-type="pmid">14729580</pub-id>
                </element-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pullarkat</surname>
                      <given-names>ST</given-names>
                    </name>
                    <name>
                      <surname>Danley</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Brynes</surname>
                      <given-names>RK</given-names>
                    </name>
                    <name>
                      <surname>Cozen</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>High lifetime incidence of adult acute lymphoblastic leukemia among Hispanics in California.</article-title>
                  <source>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</source>
                  <month>2</month>
                  <year>2009</year>
                  <volume>18</volume>
                  <issue>2</issue>
                  <fpage>611</fpage>
                  <lpage>5</lpage>
                  <comment>PubMed PMID: 19208664. Pubmed Central PMCID: 3191882</comment>
                </element-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bastaki</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Huen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Manzanillo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chande</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Balmes</surname>
                      <given-names>JR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans.</article-title>
                  <source>Pharmacogenetics and genomics</source>
                  <month>4</month>
                  <year>2006</year>
                  <volume>16</volume>
                  <issue>4</issue>
                  <fpage>279</fpage>
                  <lpage>86</lpage>
                  <comment>PubMed PMID: 16538174</comment>
                  <pub-id pub-id-type="pmid">16538174</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F1" orientation="portrait" position="float">
              <label>Figure 1</label>
              <caption>
                <title>The rs4880 <italic>SOD2</italic> SNP genotype frequencies in adult patients with ALL and association with hepatotoxicity</title>
                <p>(A) The frequency of the TT, CT, and CC genotypes in adult patients with or without hepatotoxicity. The CC genotype was significantly more frequent in patients with hepatotoxicity compared with patients without hepatotoxicity. (B) A recessive model was implemented, and showed that patients with the <italic>SOD2</italic> rs4880 CC genotype had significantly higher frequency of hepatotoxicity than those with the TT or CT genotypes (Fisher Exact test P=0.006; OR=2.5; 95% CI 1.3-4.8)</p>
              </caption>
              <graphic xlink:href="nihms-755122-f0001"/>
            </fig>
            <fig id="F2" orientation="portrait" position="float">
              <label>Figure 2</label>
              <caption>
                <title>Analysis of SOD2 mRNA expression in adult patients with ALL and association with hepatotoxicity</title>
                <p>(A) <italic>SOD2</italic> mRNA expression was measured by RT-PCR in samples obtained from patients with ALL (N=98) that completed induction therapy and two post remission cycles on CALGB10102 and compared according to their hepatotoxicity status (each circle represent different patient without hepatotoxicity and each square represent different patient with hepatotoxicity). (B) <italic>SOD2</italic> mRNA expression changes were analyzed in paired samples (pretreatment and post remission, N=30, circles represent pretreatment samples and squares represent post treatment samples).</p>
              </caption>
              <graphic xlink:href="nihms-755122-f0002"/>
            </fig>
            <fig id="F3" orientation="portrait" position="float">
              <label>Figure 3</label>
              <caption>
                <title>Analysis of SOD2 mRNA expression in adult patients with ALL and association with rs4880 SOD2 SNP genotypes</title>
                <p><italic>SOD2</italic> mRNA expression levels in (A) pretreatment (N=25) and (B) remission (N=86) samples were examined according to rs4880 genotype. (Circles, squares and triangles represent TT, CT and CC genotypes, respectively).</p>
              </caption>
              <graphic xlink:href="nihms-755122-f0003"/>
            </fig>
            <table-wrap id="T1" position="float" orientation="landscape">
              <label>Table 1</label>
              <caption>
                <p>Hepatotoxicity rates in 221 adult patients with ALL received asparaginase-based treatment</p>
              </caption>
              <table frame="void" rules="none">
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Hepatotoxicity data</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Number or patients (N)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Percent of patients (%)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Total</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">221</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">100</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>AST grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">51</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>ALT grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">82</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37.10</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Albumin grade 3</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">29</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13.12</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>ALK-Pho grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">30</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13.57</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Bilirubin grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">53</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23.98</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Hepatic failure gratia 4/5</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.26</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>ALT and AST grade 3, either grade 4 or bilirubin grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">73</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">33.03</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <table-wrap id="T2" position="float" orientation="landscape">
              <label>Table 2</label>
              <caption>
                <p>The rs4880 <italic>SOD2</italic> SNP genotype frequencies in adult patients with ALL (bold) and comparison with its frequencies in European and Hispanics cohorts.</p>
              </caption>
              <table frame="hsides" rules="none">
                <thead>
                  <tr>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                    <th colspan="3" align="center" valign="top" content-type="color:#FF0033" rowspan="1">CC vs CT vs TT analysis</th>
                    <th colspan="2" align="center" valign="top" content-type="color:#FF0033" rowspan="1">CC vs CT+TT analysis</th>
                  </tr>
                  <tr>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Cohort</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">total N</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">CC (%)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">CT (%)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">TT (%)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Chi square P value (including Hispanics)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Chi square P value (excluding Hispanics)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Chi square P Hispanics (only)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Fisher Exact P value (including Hispanics)</th>
                    <th align="center" valign="top" content-type="color:#FF0033" rowspan="1" colspan="1">Fisher Exact P value (excluding Hispanics)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>ESP-Cohort</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4368</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.207</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.504</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.288</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.029</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.16</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.01<sup><xref ref-type="table-fn" rid="TFN1">*</xref></sup></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.069</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Hap-Map-CEU</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">226</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.221</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.451</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.327</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.14</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.35</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.14</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.29</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>CEU-GENO</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">108</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.148</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.5</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.352</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.016</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.049</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.007</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.019</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>HSP-GENO</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">108</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.333</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.389</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.278</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.165</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Patients with ALL</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">192</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.281</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.45</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.245</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Patients with ALL (excluding Hispanics)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">176</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.267</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.466</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.267</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Hispanics patients with ALL</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.50</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.43</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.06</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <label>*</label>
                  <p id="P26">The chi-square with Yates’ correction was calculated instead of Fisher Exact text, due to the large number of samples</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T3" position="float" orientation="landscape">
              <label>Table 3</label>
              <caption>
                <p>The rs4880 <italic>SOD2</italic> SNP genotype frequencies in adult patients with ALL and association with hepatotoxicity.</p>
              </caption>
              <table frame="hsides" rules="none">
                <thead>
                  <tr>
                    <th align="center" valign="top" rowspan="1" colspan="1">Genotype</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Patients N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">CC N(%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">CT N(%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">TT N(%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Chi-square test P value</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Fisher Exact test P value (recessive model)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Total N (%)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">190 (100)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55 (28.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">88 (46.3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">47 (24.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>AST grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">42 (22.1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16 (38.1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">21 (50)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5 (11.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.069</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.18</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>ALT grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">68 (35.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19 (27.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">30 (44.1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19 (27.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.76</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.86</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Albumin grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">26 (13.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9 (34.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (38.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7 (26.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.69</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.49</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>ALK-phos grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">27 (14.2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (37)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9 (33.3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8 (29.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.35</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.36</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Bilirubin<sup><xref ref-type="table-fn" rid="TFN2">*</xref></sup> grade 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43 (22.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">18 (41.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (32.5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11 (25.6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.067</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.05</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Any Hepatotoxicity grade 4/5<sup><xref ref-type="table-fn" rid="TFN3">**</xref></sup></bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23 (12.1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (43.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (43.4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 (13)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.11</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.09</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Any Hepatotoxicity grade 3/4/5</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">129 (67.9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41 (31.7)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54 (41.8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34 (26.35)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.12</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.08</td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Both AST and ALT grade 3</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Or eitherAST or ALT grade 4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>61(32.1)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>26 (42.6)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>23 (37.7)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>12 (19.6)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.018</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>0.006</bold>
                    </td>
                  </tr>
                  <tr>
                    <td align="center" valign="top" rowspan="1" colspan="1">
                      <bold>Or Bilirubin 3/4</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2">
                  <label>*</label>
                  <p id="P27">Based on total and direct bilirubin measurements</p>
                </fn>
                <fn id="TFN3">
                  <label>**</label>
                  <p id="P28">Three patients had hepatic failure of Grade 5.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
